Dr Gail Carson wwwisarictghnorg ISARIC1 ERS PREPARE Amsterdam November 2017 Over the next 20 mins Definition Flu pandemic 20092010 reflection WHO Framework how to measure severity ID: 811636 Download
Tags :Download - The PPT/PDF document "Assessing severity & outcomes of SAR..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation on theme: "Assessing severity & outcomes of SARI"— Presentation transcript
Slide1
Slide2Assessing severity & outcomes of SARI
Dr Gail Carson
www.isaric.tghn.org
#ISARIC1
ERS PREPARE Amsterdam
November, 2017
Slide3Over the next 20 mins…
Definition
Flu pandemic 2009/2010 reflection
WHO Framework how to measure severity
Outcomes to consider
SPRINT SARI observational study
3
Slide4What are we talking about
SARI
An acute respiratory infection with:
history of fever or measured fever of ≥ 38 °C;
and cough;
with onset within the last 10 days;
and requires hospitalization
4
Slide5Definitions
Pandemic
An epidemic occurring worldwide or over a wide area crossing international borders and usually affecting a large number of people.
(A Dictionary of Epidemiology. Oxford. 2014
)
The worldwide spread of a new disease.
WHO, 2010
Epidemic
The occurrence in a community or region of cases of illness or health-related events clearly in excess of normal expectancy
(
A Dictionary of Epidemiology. Oxford. 2014
)
5
AlexLMX
/
iStock
Slide6How big a problem is it ?
SARI is a major public health problem. There have been multiple outbreaks of severe acute respiratory infection (SARI) over recent decades. The commonest cause of SARI is influenza.
Between pandemics, SARI is still one of the leading causes of death worldwide and places a major financial burden on health systems, given the substantial hospitalization requirements for affected patients.
There is a lack of information about the epidemiology and management of SARI patients globally, and a stated need from international bodies to establish the research infrastructure to gather this information rapidly during a time of acute need, or in an emergency such as the emergence of a new cause of SARI with epidemic potential
.
6
Slide7GlaMOR
project
WHO estimated
18,631
laboratory-confirmed
pandemic H1N1 deaths
Estimated that 2009 global pandemic respiratory mortality was ~10-fold higher than the WHO’s laboratory-confirmed mortality count.
Although the pandemic mortality estimate was similar in magnitude to that of seasonal influenza, a marked shift toward mortality among persons < 65 y of age occurred, so that many more life-years were lost.
7
Slide8Going back to 2009
Data for phase changes:
Phase 4 > 5: Is there evidence of sustained P2P transmission in ≥2 countries in 1WHO region
Phase 5 > 6: Is there evidence of sustained community transmission in multiple WHO regions?
Transmission:
How fast and far has this/will this spread?
Severity
: How bad is this? What can we expect?
What is the CFR? How can we best estimate this with limited data?
What are the age specific attack rates?
Who is most at risk?
What will the impact be on health services be... ...due to illness? ...due to fear or panic?
8
Slide9Some of the questions
Presentation and symptoms
How accurate were the case definitions? Were symptoms typical vs. atypical?
Time of onset of symptoms to time of admission and severity of presentation and outcome?
How many admitted patients received antivirals before admission?
Data needed to prepare health services
What was the availability of essential elements of medical care for these patients? e.g., antibiotics, IV fluids, O2, mechanical ventilators, ECMO equipment
What were H1N1pdm patients dying from?
Viral pneumonia, secondary bacterial infections,
etc
What are risk factors for severe infection and death? Known seasonal risk factors vs. potential new risk factors vs. no “identifiable risk factors”
Pregnancy, obesity, HIV, vulnerable/ethnic populations
Rates of infection/severe illness in HCWs
Virus information
Incubation period, duration of infectiousness, relation of virus shedding to patterns of transmission/ in different settings (e.g., hospitals with different infection control practices)
9
Slide10What is the shape of the severity pyramid ?
Slide11The impact of interventions
How effective are pharmaceutical interventions?
Vaccines and Antivirals: questions about efficacy & dosing for adult and
pediatric
patients, stockpiles, deployment plans, want vs. need vs. access
How effective are non-pharmaceutical interventions?
School closures – more data available, but only from a small number of industrialized countries
Data made available from more countries of different economic levels were needed for timely public health policy decision making
anecdotal info from other places
E.g. Mass gatherings – Masks - Social distancing - Hand washing
Importance of identifying effective and appropriate
prevention strategies in the global context when not all countries have access to pharmaceuticals
11
Slide12Pandemic Influenza Severity Assessment
(PISA)
Describe severity of an epidemic or pandemic and describe what to expect.
In 2011, the IHR review committee on the 2009 pandemic noted:
• The absence of a consistent, measurable and understandable depiction of severity of the pandemic.
• Influenza pandemics will continue to occur and influenza is grossly unpredictable.
• There needs to be a distinction between defining a pandemic and describing what to expect in a pandemic.
• … and recommended WHO should develop and apply measures that can be used to assess the
severity of every influenza epidemic.
By applying, evaluating and refining tools to measure severity every year, WHO and Member
States can be better prepared to assess severity in the next pandemic.
Inform risk management.
– The degree of severity informs risk assessments, policy decisions on planning and response, interventions and personal interest.
12
Slide1313
Slide14PISA Indicators
14
Slide15Proposed parameters
15
Slide16What Endpoints make sense
in Clinical Trials of Severe Influenza?
16
Slide1717
Slide1818
Slide1919
Slide2020
Slide21Harmonisation
21
Institut
Pasteur
Slide22SPRINT SARI
22
Slide23Acknowledgments
Maria Van
Kerkhove
, WHO
Kaat
Vandemaele
, WHO Menno de Jong, AMC
23